Funding for this research was provided by:
National Institutes of Health (R01 CA158167, K24CA172123, R01 CA166376, P50 CA121974, R01 CA227473)
National Cancer Institute (R01 CA204002)
National Center for Advancing Translational Sciences (KL2 TR000140)
Melanoma Research Alliance (308721)
American Cancer Society (30157-RSG-16-216-01-TBG)
Received: 20 March 2019
Accepted: 18 July 2019
First Online: 30 July 2019
Ethics approval and consent to participate
: The study was approved by the Yale University Institutional Review Board and done in accordance with international standards of good practice. All patients were provided written informed consent at enrollment.
: Not applicable.
: H.K. reports research grants from Merck, Bristol-Myers Squibb, and Apexigen during the conduct of the study, and personal fees from Regeneron, Alexion, Prometheus, Corvus, Nektar, Biodesix, Roche-Genetech, Pfizer, Iovance, Immunocore, and Celldex, outside of the submitted work. S.G. reports consulting work for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, and Spectrum. All remaining authors have declared no competing interests.